menu
    • menu
    [{"orgOrder":0,"company":"Chardan Healthcare","sponsor":"Sonnet BioTherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"SON-1010","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Chardan Healthcare","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Chardan Healthcare \/ Chardan Healthcare","highestDevelopmentStatusID":"12","companyTruncated":"Chardan Healthcare \/ Chardan Healthcare"},{"orgOrder":0,"company":"Chardan Healthcare","sponsor":"Eyenovia","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Tropicamide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Chardan Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Chardan Healthcare \/ Chardan Healthcare","highestDevelopmentStatusID":"12","companyTruncated":"Chardan Healthcare \/ Chardan Healthcare"}]

    Find Clinical Drug Pipeline Developments & Deals by Chardan Healthcare

    Menu

    Chardan Healthcare

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Chardan Healthcare

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Chardan Healthcare

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tropicamide,Phenylephrine Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Recipient : Eyenovia

                            Deal Size : $1.3 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Eyenovia, Inc. Announces Pricing of $1.3 Million Registered Direct Offering

                            Details : The Company intends to use the net proceeds for the commercialization activities for Mydcombi, the first and only FDA-approved fixed dose combination ophthalmic spray for pupil dilation.

                            Brand Name : Mydcombi

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 25, 2024

                            Lead Product(s) : Tropicamide,Phenylephrine Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Recipient : Eyenovia

                            Deal Size : $1.3 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Chardan Healthcare

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Chardan Healthcare

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SON-1010

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Sonnet BioTherapeutics

                            Deal Size : $5.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Sonnet Prices $5M Public Offering At Market Under Nasdaq Rules

                            Details : Sonnet will use the net proceeds for research and development, including SON-1010, a candidate immunotherapeutic recombinant drug, targeting solid tumors.

                            Brand Name : SON-1010

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            November 06, 2024

                            Lead Product(s) : SON-1010

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Sonnet BioTherapeutics

                            Deal Size : $5.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth